alexa Future Treatment of Hepatitis C: What will be the Fate of Ribavirin? | OMICS International | Abstract
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

Future Treatment of Hepatitis C: What will be the Fate of Ribavirin?

Melissa Palmer*

Department of Clinical Research and Head of Hepatology Kadmon Corporation, New York University, USA

*Corresponding Author:
Melissa Palmer
Senior Vice President
Department of Clinical Research
and Head of Hepatology Kadmon Corporation
New York University, USA
E-mail: [email protected]

Received date: January 02, 2013; Accepted date: January 03, 2013; Published date: January 05, 2013

Citation: Palmer M (2013) Future Treatment of Hepatitis C: What will be the Fate of Ribavirin? J Gastroint Dig Syst 3:e113. doi:10.4172/2161-069X.1000e113

Copyright: © 2013 Palmer M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

When I began my career as a hepatologist in 1988 there were no treatments for viral hepatitis. In fact, hepatitis C (HCV), then known as non-A, non-B (NANB) hepatitis, was not discovered until the following year. Almost a decade passed before treatment for HCV became available that resulted in acceptable Sustained Virologic Response (SVR) rates (now known to be consistent with virologic cure) - a combination of Interferon alpha (IFN) plus Ribavirin (RBV). Prior to this pairing, less than 10% of HCV patients achieved a SVR when treated with IFN alone. With combination therapy, SVR rates rose to approximately 40-50%.

Recommended Conferences
Share This Page
Top